Shanghai - Delayed Quote CNY

North China Pharmaceutical Company.Ltd (600812.SS)

5.95
0.00
(0.00%)
At close: May 14 at 3:00:02 PM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
9,886,317.76
9,869,575.82
10,120,201.38
10,499,947.07
10,384,575.26
Cost of Revenue
6,755,874.90
6,714,658.59
6,883,613.72
6,995,026.13
6,702,615.51
Gross Profit
3,130,442.86
3,154,917.23
3,236,587.66
3,504,920.94
3,681,959.75
Operating Expense
2,388,545.58
2,425,020.79
2,639,849.13
2,726,578.18
3,006,505.81
Operating Income
741,897.28
729,896.43
596,738.53
778,342.76
675,453.94
Net Non Operating Interest Income Expense
-417,550.64
-443,347.15
-484,234.60
-574,879.05
-568,147
Pretax Income
354,960.12
309,832.51
158,535.69
-565,074.48
134,905.01
Tax Provision
96,161.99
94,865.99
109,147.81
113,707.09
99,522.94
Net Income Common Stockholders
166,331.51
126,992.37
4,890.35
-689,231.50
18,727.45
Basic EPS
0.10
0.07
0.00
-0.40
0.01
Diluted EPS
0.10
0.07
0.00
-0.40
0.01
Basic Average Shares
1,726,289.75
1,716,113.11
1,630,115.74
1,714,506.22
1,702,495.14
Diluted Average Shares
1,726,289.75
1,716,113.11
1,630,115.74
1,714,506.22
1,702,495.14
Total Operating Income as Reported
356,918.10
311,681.16
156,453.22
-567,633.67
136,031.31
Rent Expense Supplemental
--
8,077.86
9,239.11
6,321.46
5,670.97
Total Expenses
9,144,420.47
9,139,679.39
9,523,462.85
9,721,604.30
9,709,121.32
Net Income from Continuing & Discontinued Operation
166,331.51
126,992.37
4,890.35
-689,231.50
18,727.45
Normalized Income
188,969.92
153,777.64
15,682.35
-60,407.99
20,281.93
Interest Income
25,431.81
25,255.79
27,666.24
40,147.78
87,505.84
Interest Expense
435,551.68
458,698.02
501,895.72
599,391.11
642,691.24
Net Interest Income
-417,550.64
-443,347.15
-484,234.60
-574,879.05
-568,147
EBIT
790,511.80
768,530.53
660,431.40
34,316.64
777,596.25
EBITDA
790,511.80
1,631,930.37
1,538,477.18
813,337.18
1,480,828.63
Reconciled Cost of Revenue
6,755,874.90
6,714,658.59
6,883,613.72
6,995,026.13
6,702,615.51
Reconciled Depreciation
--
863,399.84
878,045.77
779,020.54
703,232.38
Net Income from Continuing Operation Net Minority Interest
166,331.51
126,992.37
4,890.35
-689,231.50
18,727.45
Total Unusual Items Excluding Goodwill
-31,050.20
-38,605.77
-14,389.34
-838,431.35
-2,072.65
Total Unusual Items
-31,050.20
-38,605.77
-14,389.34
-838,431.35
-2,072.65
Normalized EBITDA
821,562
1,670,536.15
1,552,866.52
1,651,768.53
1,482,901.27
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-8,411.79
-11,820.50
-3,597.33
-209,607.84
-518.16
12/31/2021 - 1/14/1994

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

WSG.SG China Traditional Chinese Medicine Holdings Co Ltd
0.2300
0.00%
 
WSG.BE China Traditional Chinese Medicine Holdings Co Ltd
0.2400
-2.44%
 
DEVA.IS Deva Holding A.S.
59.15
-1.33%
 
CHIZF China Traditional Chinese Medicine Holdings Co. Limited
0.3360
0.00%
 
WUHN Wuhan General Group (China), Inc.
0.0001
0.00%
 
HKMPY Hikma Pharmaceuticals PLC
53.08
0.00%
 
CPHI China Pharma Holdings, Inc.
2.2200
+5.71%